Here we show that the novel RAF/MEK inhibitor CH5126766 suppresses the cell growth of RAS-mutated cells as well as BRAF-mutated cells, which raises the possibility that CH5126766 is promising for the therapy against RAS-mutated malignant tumors. This evidence concerns the gene MAP2K7 and cancer.